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Human mitochondria contain their own ge-
nome, encoding 13 polypeptides that are syn-
thesized within the organelle. The molecular
processes that govern and facilitate this mito-
chondrial translation remain unclear. Many key
factors have yet to be characterized—for exam-
ple, those required for translation termination.
All other systems have two classes of release
factors that either promote codon-specific hy-
drolysis of peptidyl-tRNA (class I) or lack spec-
ificity but stimulate the dissociation of class I
factors from the ribosome (class II). One human
mitochondrial protein has been previously iden-
tified in silico as a putative member of the class I
release factors. Although we could not confirm
the function of this factor, we report the identi-
fication of a different mitochondrial protein,
mtRF1a, that is capable in vitro and in vivo of
terminating translation at UAA/UAG codons.
Further, mtRF1a depletion in HeLa cells led
to compromised growth in galactose and in-
creased production of reactive oxygen species.
INTRODUCTION
A central mitochondrial function is that of oxidative phos-
phorylation, the process of coupling respiration to ATP
production. Thirteen of the polypeptides critical for this
function are encoded by the mitochondrial genome
(mtDNA). Mitochondrial protein synthesis is therefore
central to the life of aerobic eukaryotic cells; however,
our understanding of mammalian mitochondrial gene
expression is far from complete, particularly concerning
the mechanisms governing mitochondrial protein synthe-
sis. It is essential that we redress this situation, as it has
become increasingly clear that defects of mitochondrialMoleculartranslation constitute an important subset of mitochon-
drial disorders (Coenen et al., 2004; Jacobs and Turnbull,
2005; Miller et al., 2004; Smeitink et al., 2006; Valente
et al., 2007).
The mitochondrial translation apparatus employs a dif-
ferent codon usage from the universal code, with some
species decoding AUA as methionine and the majority
converting the universal STOP codon UGA into a trypto-
phan. Thus, most mitochondrial translation systems
have reduced the number of termination codons from
three to two (Elzanowski and Ostell, 2000). Although the
human mitochondrial code also employs these two
changes, it varies still further by commandeering two ad-
ditional termination codons, AGA and AGG, that would
conventionally encode arginine (Barrell et al., 1979).
Once the translation complex has reached a termination
codon, the completed protein must be dissociated from
the final tRNA, the ribosome, and its cognate mRNA.
The proteins responsible for fulfilling these functions are
the release factors (RFs), of which there are two classes
(for review, see Kisselev et al., 2003; Poole and Tate,
2000). Class I is codon specific with peptide motifs that
distinguish the STOP codons. In prokaryotic RFs, this is
an SPF or PXT tripeptide motif (Ito et al., 2000; Nakamura
et al., 2000). There is also a GGQ loop/motif facilitating the
termination of translation by hydrolysis of the ester bond
between the tRNA and the nascent polypeptide (Frolova
et al., 1999; Seit-Nebi et al., 2001). Eubacterial and
eukaryotic cytosolic release factors differ in their class I
constituents. Eubacteria utilize three STOP codons and
require two release factors, RF1 and RF2. Both recognize
UAA, but RF1 also interacts with UAG and RF2 with UGA.
Thus, although each bacterial RF recognizes a pair of
STOP codons, both are necessary for appropriate trans-
lation termination of the entire mRNA population. Most
eukaryota and archaebacteria utilize the same three stop
codons (UAA, UAG, and UGA), but each organism re-
quires only a single omnipotent protein, named eRF1 or
aRF1, respectively, that can recognize all three STOP trip-
lets (Frolova et al., 1999; Konecki et al., 1977). This leavesCell 27, 745–757, September 7, 2007 ª2007 Elsevier Inc. 745
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semble more closely the eukaryota and archaebacteria
and have evolved a single release factor that can recog-
nize all four codons that are used, or whether they follow
the eubacterial paradigm of two RFs, each recognizing
a pair of stop codons, which would more closely reflect
their a-proteobacterial origins.
Thus far, no human mitochondrial release factor has
been characterized. A candidate, mtRF1, was proposed
several years ago from bioinformatic analyses (Zhang
and Spremulli, 1998) and has since been assimilated
into the scientific literature (for example, Antonicka et al.,
2006; Askarian-Amiri et al., 2000; Bulygin et al., 2002;
Chavatte et al., 2003; Frolova et al., 2002; Kisselev et al.,
2003; Oparina et al., 2005; Petry et al., 2005; Smeitink
et al., 2006). Class I release factors of the RF1 type contain
a PXT tripeptide motif responsible for codon recognition.
Human mtRF1, however, exhibits a hexapeptide PEVGLS
across this region.
Here we report that we have now identified an alterna-
tive gene product with greater similarity across the tripep-
tide recognition motif of the bacterial RF1. Moreover, we
ascribe mitochondrial localization and release activity to
this protein, mtRF1a, which exhibits specific recognition
of the main codons used, UAA and UAG, consistent with
it being a release factor in human mitochondria.
RESULTS
Human mtRF1 Is a Mitochondrial Protein
A number of papers now state that human mitochondria
have a single release factor, mtRF1, which was identified
in silico a number of years ago (Zhang and Spremulli,
1998). To identify whether this protein is indeed mitochon-
drial, we generated a GFP fusion construct C-terminal to
the predicted mtRF1 N-terminal targeting sequence.
HeLa cells were transiently transfected and after 24 hr
were treated with mitotracker-CMH2X ROS to visualize
the mitochondria. Concordance of the fluorescence sig-
nals indicated mitochondrial localization of the fusion
protein (Figure 1A).
Does HumanmtRF1 Function as a Release Factor?
To assess whether mtRF1 could function as a release fac-
tor, we adopted an in vitro and an in vivo approach. In vitro
release factor assays were performed essentially as es-
tablished by Caskey and colleagues (Caskey et al.,
1971). Briefly, ribosomes were incubated with AUG syn-
thetic triplet and f[3H]Met-tRNAMet to load the ribosomal
P site prior to addition of purified mtRF1 and the synthetic
stop codon to be assessed. Free f[3H]Met was then quan-
tified to indicate release activity. The exact size of the
N-terminal presequence that might be cleaved from the
full-length protein upon mitochondrial import is unknown,
and predictions from targeting programmes vary from
17 up to 70 residues. Moreover, sequence alignment indi-
cates that the first 63 amino acids of the mtRF1 N-terminal
extension do not align with the bacterial RF1. Therefore, to746 Molecular Cell 27, 745–757, September 7, 2007 ª2007 Elsesimulate possible mature polypeptides without the loss of
recognized functional domains, two proteins carrying N-
terminal truncations and increased solubility, mtRF1D49
and mtRF1D69 (data not shown), were purified. These
were tested against the universal and mitochondrial-
specific stop codons, but no activity could be detected
with UAA, AGA, or AGG codons (Figure 1B).
For in vivo studies, we assessed whether human mtRF1
could suppress the phenotype caused by loss of the
endogenous release factor from yeast. Mutations of
S. cerevisiae MRF1 cause a respiratory dysfunction asso-
ciated with the loss of intact mtDNA (Pel et al., 1992). Such
mtDNA instability is known to result from defects in the
general mitochondrial translation machinery (Myers
et al., 1985). Expression of the entire human mtRF1
cDNA in a heterozygous Dmrf1 rho+ diploid, followed by
sporulation, did not yield any Dmrf1 spores that could
grow on nonfermentable carbon sources (glycerol,
Figure 1C). Similarly, there was no restoration of cyto-
chrome spectra, consistent with a lack of mitochondrial
protein synthesis and respiratory complex assembly
(data not shown). In fact, the Dmrf1 spores producing
human mtRF1 could still not maintain their mtDNA. This
raised the possibility that complementation occurred but
was too weak to allow mtDNA maintenance, thus prevent-
ing nonfermentable growth. To address this problem,
a new mrf1-deleted strain was engineered in the fission
yeast Schizosaccharomyces pombe, a petite-negative
yeast, for which mtDNA loss events are highly counter-
selected. The Dmrf1Sp strain showed reduced growth at
28C on galactose, which forces respiration, and it
stopped growing at 36C on the same medium (Figure 1D,
see Figure S4B in the Supplemental Data available with
this article online) but retained mtDNA (Figure S1). Trans-
fectants of this strain expressing the cDNA encoding
human mtRF1 were also unable to respire, and there
was no restoration of growth on glycerol/ethanol or galac-
tose, as shown in Figure 1D, despite the presence of an
intact mtDNA.
Identification of an Alternative Candidate Human
Mitochondrial Release Factor
The lack of release activity in vitro could have been due to
the necessity to use the heterologous bacterial 70S ribo-
somes rather than 55S mitoribosomes. To date, it has
not been possible to establish a reproducible in vitro assay
with mammalian mitoribosomes, unlike with yeast compo-
nents (Askarian-Amiri et al., 2000), perhaps explained by
recent cryo-electron microscopy studies, which have re-
vealed that isolated mammalian mitoribosomes retain de-
acylated mt-tRNA in the P site (Sharma et al., 2003). Sec-
ond, the failure of mtRF1 to restore respiration in either of
the yeast Dmrf1 strains may be explained by yeast Mrf1p
recognizing only UAA/UAG as termination codons (as all
yeast mt-mRNAs contain UAA or UAG as stop codons),
while those recognized by the human mtRF1 could po-
tentially be AGG and AGA. If this is the case, then there
may be a second human mitochondrial release factor.vier Inc.
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Translation Termination in Human MitochondriaFigure 1. Human mtRF1 Is a Mitochondrial Protein with No Detectable Release Factor Activity
(A) Human mtRF1 is targeted to mitochondria. HeLa cells were transiently transfected for 24 hr with a construct expressing 290 N-terminal residues of
mtRF1 fused to GFP. Cells were also stained to visualize mitochondria (mitotracker CMH2X-Ros) and nuclei (DAPI). Fluorescence images were cap-
tured and mitochondrial colocalization of the fusion protein confirmed by superimposition of the green and red signals in a linescan of the image (line
visible in upper panel). An image typical of the three independent transfections is shown.
(B) Purified mtRF1 does not induce translation termination in vitro. Human mtRF1 lacking the N-terminal 49 residues was purified and used to assess
translation termination from 5 pmol ribosomes programmed with the synthetic codon (400 pmol) indicated. Release factor activity was measured by
the hydrolysis of f[3H]met from its cognate tRNAMet as detailed in the Supplemental Experimental Procedures. Nonlimiting amounts of both E. coliRF1
(50 pmol) and UAA triplet (400 pmol) were used in tandem as a positive control for the assay. Standard errors were calculated from a minimum of eight
repeats.
(C) Human mtRF1 fails to restore respiratory competence in S. cerevisiae Dmrf1. Diploids producing human mtRF1 or containing vector alone were
generated from the Dmrf1 strain crossed to the wild-type CW252/A. Following sporulation, asci were dissected and resultant haploid sister spores
(A–D) assessed for presence of the plasmid (uracil), resistance to geneticin G418 showing deletion of MRF1Sc, and growth on a nonfermentable
carbon source (glycerol).
(D) Human mtRF1 fails to restore respiratory competence in S. pombe Dmrf1. The new fission yeast strain devoid of endogenous mitochondrial
release factor NB329 (Experimental Procedures) and its isogenic wild-type strain NB205-6A were transformed with either empty vector or one pro-
ducing human mtRF1. Transformants were patched on uracil-free minimal medium selecting for the plasmid, replicated onto complete galactose or
glycerol plates, and incubated at 28C.Searching of the human databases revealed a second
candidate that we will call mtRF1a (UniprotKB/TrEMBL
Q96EX4). This predicted polypeptide of 380 amino acids
shows an overall sequence identity of approximately
42% with mtRF1, 34% with yeast mRFs (S. pombe,
S. cerevisiae, K. lactis), 40% with bacterial RF1s, and
41% similarity to the RF from a close evolutionary relative
R. prowazeckii (Andersson et al., 1998; Gray, 1998)
(Figure S2). Moreover, mtRF1a contains a PXT motif
that more closely resembles other RF1s, containing the
triamino acid recognition motif PKT, rather than the hexa-
peptide sequence in mtRF1 (Table 1).MolecularAs with mtRF1, a C-terminal GFP fusion protein con-
struct was generated for mtRF1a and transiently trans-
fected into HeLa cells before staining with mitotracker
after 24 hr. Mitochondrial targeting was shown by colocal-
ization of the fluorescence signals (Figure 2A). To confirm
intramitochondrial uptake, import experiments were per-
formed with in vitro-translated 35S-labeled mtRF1a and
isolated mitochondria (Figure 2B and Supplemental Ex-
perimental Procedures). Import was shown to be depen-
dent on a mitochondrial membrane potential (FCCP, lanes
4 and 5) and resulted in cleavage of the presequence
(lanes 2 and 3). The matured protein was resistant toCell 27, 745–757, September 7, 2007 ª2007 Elsevier Inc. 747
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Translation Termination in Human MitochondriaTable 1. Comparison of the Primary Sequence Covering the Stop Codon Recognition Motif of RF1-Type Release
Factors from Various Organisms
Species Sequence Identity Accession Number Cytosolic/Mitochondrial
E. coli HRVQRVPAT---ESQGRIHTS 18/18 P07011 Cytosolic
Human HRVQRIPEVGLSSRMQRIHTG 10/21 BC042196 Mitochondrial
Human HRVQRVPKT---EKQGRVHTS 15/18 BC011873 Mitochondrial
Streptomyces coelicolor HRVQRVPAT---ESQGRIHTS 18/18 CAB94531 Cytosolic
Paracoccus denitrificans HRVQRVPET---ESGGRIHTS 16/18 YP_914701 Cytosolic
Bacillus subtilis HRVQRVPET---ESGGRIHTS 16/18 CAA89884 Cytosolic
Rickettsia prowazekii HRVQRIPET---ESQGRIHTS 16/18 Q9ZD21 Cytosolic
Kluyveromyces lactis HRVQRVPAT---ESKGRTHTS 16/18 P41767 Mitochondrial
Saccharomyces cerevisiae HRVQRIPST---ETKGRTHTS 15/18 P30775 Mitochondrial
Schizosaccharomyces pombe HRVQRTPAT---ETKGRVHTS 14/18 CAA90504 Mitochondrial
Caenorhabditis elegans HRVQRVPVN-----DSRMHTS 11/18 O44568 Mitochondrialadded Proteinase K, confirming mitochondrial uptake
(lane 3).
Any factor involved in mitochondrial protein translation
would be predicted to be present in all cell types. Antisera
were raised against purified recombinant mtRF1a and af-
finity purified. Mitochondrial protein isolated from human
skeletal muscle and a variety of human cell lines were an-
alyzed by western analysis, and mtRF1a was found to be
ubiquitous (Figure 2C). Further, by comparison of HeLa
extracts against a standard curve of purified mtRF1a, we
were able to calculate approximately 30,000 molecules
per cell (data not shown).
Human mtRF1a Is a Translation Release Factor
Purified recombinant mtRF1a was tested in the termina-
tion assay described above. Initial assays showed release
of f[3H]Met when either UAA or UAG was used as a syn-
thetic stop codon, confirming that mtRF1a could function
as a release factor. Assay conditions were optimized for
the human mitochondrial release factor (Figure S3). Using
these assay parameters, the human recombinant mtRF1a
was interrogated with a full panel of codons. Figure 2D
clearly demonstrates that mtRF1a mediated codon-
specific release of f[3H]Met from the termination complex.
There is significant recognition of UAA and UAG stop co-
dons by human mtRF1a but only residual noncatalytic
levels comparable to those obtained when no codon
was present for the noncognate stops AGA and AGG. Cru-
cially, the UGA codon, encoding tryptophan in the human
mitochondrion, did not stimulate release activity. Elon-
gating the stop codon 30 to include three further adeno-
sine residues to mimic the context with the poly(A)
tail made no significant change to the release activity
observed.
Although the human mtDNA utilizes four triplet se-
quences as stop signals, the usage is not evenly distrib-
uted at the end of the 13 mitochondrial open reading
frames (ORFs) (Anderson et al., 1981). The noncanonical748 Molecular Cell 27, 745–757, September 7, 2007 ª2007 ElsAGA and AGG stops are used only once each, for MTCOI
and by MTND6, respectively. Of the remaining 11 ORFs,
MTCO2 and MTATP8 employ UAG as stop codons, and
the final nine all use UAA encoded directly by the genome
or completed by the addition of a poly(A) tail. Thus, 11 of
the 13 transcripts utilize stop signals recognized by
human mtRF1a.
In vivo analyses were performed concomitantly. Com-
plementation by human mtRF1a was assessed in both
Dmrf1 yeast strains as described for mtRF1 (Figure 3).
Western blots of cell fractions confirmed the mitochon-
drial localization of the human protein in yeast, albeit at dif-
ferent level to wild-type. Whereas only a faint mtRF1a sig-
nal was detected in S. cerevisiae mitochondria, a strong
signal was obtained in S. pombe mitochondria, with
a small fraction of protein being detected in the postmito-
chondrial fraction, suggesting that in S. pombe the human
protein was either better expressed, more stable, and/or
more efficiently imported into mitochondria (Figure S4A).
In contrast to expression of mtRF1, the presence of hu-
man mtRF1a was sufficient to stably maintain mtDNA in
the S. cerevisiae Dmrf1 strain (data not shown) and restore
growth on respiratory substrates for both yeasts (glycerol
forS. cerevisiae, Figure 3A; galactose and glycerol at 28C
for S. pombe, Figure 3B; and 36C on galactose for
S. pombe, Figure S4B), consistent with the observed in-
crease in cytochromes (Figures 3A and 3B, right-hand
panels) and partial restoration of steady-state levels of
mitochondrial proteins (Cox2, Cyt b, Figure 3C).
Mitochondrial translation in several S. cerevisiae strains
was also monitored by in vivo 35S labeling of mitochondrial
proteins. No de novo synthesis was detected in the dele-
tion mutant. In contrast, the isogenic strain producing the
wild-type yeast Mrf1p exhibited high levels of protein
synthesis. Production of the human mtRF1a also resulted
in mitochondrial translation, albeit at decreased levels
when compared to the wild-type strain (Figure 3D). These
data confirm that mtRF1a can function to restoreevier Inc.
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(A) Human mtRF1a is targeted to mitochondria. HeLa cells were transiently transfected (24 hr) with a construct expressing 357 N-terminal residues of
mtRF1a fused to GFP. Cells were also stained to visualize mitochondria (mitotracker CMH2X-Ros) and nuclei (DAPI). Fluorescence images were cap-
tured and mitochondrial colocalization of the fusion protein confirmed by superimposition of the green (fusion protein) and red (mitochondrial) signals
as shown in the far right panel. The image shown is representative of three independent repeats.
(B) Human mtRF1a is imported into mitochondria and matured. Full-length 35S-radiolabeled mtRF1a was in vitro synthesized (lane 1) and incubated
with rat liver mitochondria. Under import conditions, two products are visible, the full-length preprotein and the mature protein (lane 2). Components
(FCCP, Proteinase K) were added as indicated.
(C) Human mtRF1a is found in the mitochondria of all cell lines and tissues analyzed. Human Hep G2, HEK293, and HeLa cell (C60 mg) or mitochondrial
(M20 mg) lysates along with human skeletal muscle mitochondria (SkM–M18 mg) were prepared and subjected to western blot analysis with anti-
mtRF1a antibodies. A single protein of approximately 40 kDa was visible in all cell/tissue types tested and found exclusively in the mitochondrial frac-
tion (not in postmitochondrial supernatants, data not shown). No crossreactivity was noted with purified mtRF1 (data not shown).
(D) Human mtRF1a has release factor activity with UAA and UAG, but not UGA codons. Release assays were performed with 50 pmol mtRF1a and
5 pmol ribosomes, as detailed in the Experimental Procedures. Ribosomes were programmed independently with five triplet codons (400 pmol), four
of which are termination codons in human mitochondria (UAA/G, AGA/G), and UGA that encodes tryptophan in mitochondria but acts as a termination
codon in the cytosol. No codon controls were also performed. Standard errors were calculated from a minimum of three or a maximum of 11 repeats.translation in yeast strains deficient in endogenous mito-
chondrial translation termination factors.
Depletion of Human mtRF1a Causes
a Growth Phenotype
To determine the role of human mtRF1a in the mitochon-
drion, siRNA was used to deplete the factor in HeLa cells.
Three siRNA molecules were designed to different posi-
tions of the mtRF1a transcript, and each was shown to de-
crease the steady-state level of the release factor by more
than 75% (Figure 4A). Crude analysis of cell proliferation
revealed lower levels of confluency when cells were mon-
itored for 6 days with each siRNA independently (data not
shown). As the three siRNA duplexes gave a similar phe-
notype, all subsequent experiments were performed
with siRNA 2 alone. Detailed cell counts were then per-
formed for siRNA2- or nontargeted siRNA-treated HeLaMolecularcells cultured in standard DMEM-promoting glycolysis or
glucose-free media supplemented with galactose to force
dependence on oxidative phosphorylation. As can be
seen (Figure 5A), the siRNA2-treated cells showed an in-
crease in population doubling time, which was particularly
marked when cells were forced to respire in the galactose
media.
Depletion of mtRF1a Does Not Affect the
Steady-State Levels of Mitochondrially
Encoded RNA or Protein
To explore the exact mechanism causing this phenotype,
we analyzed mitochondrially encoded RNA and protein.
Figure 4 shows that the steady states of the mitochondri-
ally encoded members of the OXPHOS complexes I (ND6)
and IV (COXI and COXII) were virtually unaffected after
3 or 6 days of siRNA-mediated mtRF1a knockdownCell 27, 745–757, September 7, 2007 ª2007 Elsevier Inc. 749
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Translation Termination in Human MitochondriaFigure 3. Human mtRF1a Can Suppress the Respiratory Deficiency in Dmrf1 Budding and Fission Yeast
(A) Human mtRF1a restores respiratory growth of S. cerevisiae lacking a mitochondrial release factor. The heterozygous Dmrf1 diploid strain (Fig-
ure 1C) was transfected with empty vector or encoding human mtRF1a prior to sporulation and tetrad analysis as described. The right panel shows
low-temperature spectra of cells grown on glucose (Dmrf1) or glycerol (WT and Dmrf1 + HmtRF1a) medium.
(B) Human mtRF1a can function in fission yeast mitochondria. The Dmrf1Sp strain NB329 or the isogenic wild-type was transformed with either con-
trol vector or one producing mtRF1a. Transformants patched on uracil-free medium were replicated onto galactose or glycerol/ethanol medium and
incubated at 28C. Spectral analysis from Dmrf1 cells (glucose), WT, and Dmrf1cells expressing MTRF1a (galactose) is shown in the right panel.
(C) Human mtRF1a partially restores the level of mitochondrial gene products in yeast. (Left panel) Western analysis of S. cerevisiae respiratory com-
plex subunits Cox2, Atp4, Cyt b from wild-type + empty vector (lane 1), Dmrf1Sc + empty vector (lane 2), Dmrf1Sc + human mtRF1a (lane 3), and
Dmrf1Sc + Mrf1Sc (lane 4). The right panel shows total cell extracts of the S. pombe Dmrf1 strain transformed with either the empty vector (lane750 Molecular Cell 27, 745–757, September 7, 2007 ª2007 Elsevier Inc.
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Does Not Grossly Affect Human Mito-
chondrial Protein Synthesis
(A) Steady-state levels of mtDNA-encoded
proteins are unaffected by depletion of
mtRF1a. HeLa cells were exposed to siRNA
molecules targeting three different regions of
the mtRF1a-encoding mRNA sequence (lanes
1–3) or to an untargeted siRNA (siRNA-N, lane
4) for 6 days, and cell lysates (30 mg) were pre-
pared. Control lysates were made from oligo-
fectamine alone (lane 5) and untreated cells
(Con, lane 6). Western blots were performed
with antibodies against mitochondrial transla-
tion products (COX1 cytochrome c oxidase
subunit 1; COX2, cytochrome c oxidase sub-
unit II; ND6 NADH CoQ oxidoreductase subunit
6). Porin was used as a nuclear encoded con-
trol to confirm equal loading. Purified mtRF1a
(5 ng) is loaded in lane 7. The anti-mtRF1a ex-
periment was overexposed to show the level
of depletion. The blot accurately reflects three
independent experiments.
(B) De novo synthesis of mitochondrial proteins
is unaffected by depletion of mtRF1a. Cyto-
solic protein synthesis of HeLa cells grown in
the presence of siRNA targeted to MTRF1a
(siRNA2-mtRF1a) or untargeted (siRNA-N) for
4 days was inhibited by the addition of emetine,
allowing the incorporation of 35S-labeled met/
cys directly into the 13 de novo-synthesized
mitochondrial proteins. Equal amounts of total
cell protein (20 mg) were separated through
a 15% SDS PAG and exposed to a Phosphor-
Imager as described. Polypeptides were des-
ignated based on their mobilities as described
in Chomyn (1996).
(C) OXPHOS complexes are present at normal
steady-state levels in cells depleted of mtRF1a.
HeLa cells were exposed to mtRF1a targeted
(lane 1) or untargeted (lane 2) siRNA for
6 days prior to digitonin permeabilisation and
preparation for BN-PAGE as described. Fol-
lowing separation, complexes were identified
using antisera as detailed. Complex I, anti-
39kDa antibody; complex II, anti-SDH 70 kDa
antibody; complex III, anti-core 2 antibody;
complex IV, anti-COX1 antibody.
(D) Respiratory coupling is unaffected in cells depleted of human mtRF1a. HeLa cells (1–23 106) grown in targeted (siRNA2-mtRF1a) and untargeted
(siRNA-N) siRNA for 3 days were subjected to high-resolution respirometry as detailed. Standard errors were calculated from three measures of re-
spiratory control and capacity. UCR compares the fully uncoupled and resting respiratory rates to give an indication of the respiratory reserve and RCR
compares the fully uncoupled respiratory rates to the oligomycin inhibited state 4 respiratory rate, while RCRp combines these ratios to indicate the
level of phosphorylation-related respiratory capacity.
(E) The poly(A) tail of mitochondrial mRNA is unaffected by depletion of mtRF1a. RNA was isolated from HeLa cells depleted of mtRF1a (lanes 1,
siRNA1; lanes 2, siRNA2; lanes 3, siRNA3) and untargeted control siRNA treated (lanes 4) before the poly(A) tail length was assessed for several
mt-mRNAs as previously described (Temperley et al., 2003). Poly(A) profiles are shown for transcripts MTCOI, MTCOII, MTND1, and MTND3.(Figure 4A). This was consistent with the absence of any
effect on de novo mitochondrial protein synthesis
(Figure 4B). One corollary was that nascent polypeptidesMolecularremained associated with ribosomes, affecting the as-
sembly of the nascent polypeptide into OXPHOS com-
plexes. Thus, to assess the levels of fully assembled1), or plasmids producing the human mtRF1a (lane 2) or Mrf1Sp (lane 3) proteins, and analyzed by western blotting with antibodies recognizing the
S. pombe Cox2 or human Hsp60 protein as a loading control.
(D) Mitochondrial translation is restored in the presence of human mtRF1a. This was measured with 35S-methionine/cysteine incorporation as detailed
in the Experimental Procedures. Strains were as follows: lane 1, Dmrf1Sc NB345 + vector encoding human mtRF1a; lane 2, Dmrf1Sc NB345 + empty
vector; lane 3, WT NB346 + empty vector.Cell 27, 745–757, September 7, 2007 ª2007 Elsevier Inc. 751
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Increased Mitochondrial ROS Production, and Mitochondrial
Mass
(A) Cell growth is compromised by depletion of mtRF1a. Multiple ali-
quots of HeLa cells were exposed to targeted (siRNA2-mtRF1a) and
nontargeted (siRNA-N) interfering RNAs for up to 6 days in glucose
(promoting glycolysis) or galactose (forcing oxidative respiration) me-
dia with cell counts performed each day. Cell numbers are presented
in a semi-log plot. The numbers represent a mean ± SEM from four
independent wells.
(B) Superoxide levels and mitochondrial mass are elevated in cells de-
pleted of mtRF1a. HeLa cells were exposed to targeted (white) and752 Molecular Cell 27, 745–757, September 7, 2007 ª2007 Elsecomplexes, Blue Native PAGE was employed. After sepa-
ration of intact complexes, no apparent difference was
seen in the steady-state level or migration of these multi-
subunit enzymes (complexes I, III, and IV, Figure 4C), sug-
gesting that nascent peptides are eventually released
from the ribosome.
Although the levels of OXPHOS complexes were similar,
it was possible that electron transfer rates or coupling to
ATP synthesis was affected, causing the growth pheno-
type. Polarographic analysis of control and siRNA-treated
cells was performed, and results are shown in Figure 4D.
No significant differences in coupled or uncoupled rates
of electron transfer were found, and the respiratory control
ratios were comparable between samples, again consis-
tent with release of the nascent and assembled polypep-
tide from the ribosome.
Critically, a previous report has demonstrated that loss
of an mt-mRNA termination codon does not prevent pro-
tein synthesis, complex formation, or activity (Temperley
et al., 2003). Thus, it appears that neither loss of the termi-
nation codon nor depletion of the release factor has an ef-
fect on the steady-state or de novo synthesis of human
mitochondrial proteins. In those transcripts lacking termi-
nation codons, there was marked translation-dependent
degradation of the poly(A) tail and rapid turnover (Temper-
ley et al., 2003). Northern analysis (data not shown) and
MPAT assays on MTCO1, 2 and MTND1, 3 transcripts,
however, confirmed that depletion of mtRF1a caused
no effect on mt-mRNA stability or poly(A) tail length
(Figure 4E).
Depletion of mtRF1a Causes Increased
Mitochondrial ROS Production, Mitochondrial
Mass, and mtDNA Copy Number
The role of a release factor is to promote hydrolysis of the
ester bond linking the nascent peptide to the terminal
tRNA. Hydrolysis can occur independent of the factor,
which would potentially make the release factor redun-
dant, but this noncatalytic rate is believed to be relatively
slow (W.T., unpublished data). Moreover, peptidyl-tRNA
can also ‘‘drop off’’ the ribosome (reviewed in Das and
Varshney, 2006), and a recent report of a human mito-
chondrial peptidyl-tRNA hydrolase, PTH2 (De Pereda
et al., 2004), suggests this enzyme would hydrolyze the
peptidyl-tRNA complex, allowing the recycling of the
tRNA. It is therefore difficult to predict the exact defect
that would occur on depletion of the factor in human
mitochondria. Our initial data showed that a growth
nontargeted (black) siRNA. Superoxide (SOX) was measured with Mi-
toSOX probes and peroxide (DHR) with dihydrorhodamine 123. Levels
were measured at day 3 and compared to levels in untreated control
cells. The fold increase is shown as a mean ± SEM from at least three
independent experiments (p < 0.01 comparing nontargeted to targeted
values for mitoSOX and DHR). Mitochondrial mass per cell was mea-
sured with the cardiolipin selective dye, NAO. Changes in mtDNA con-
tent relative to the nuclear DNA were calculated by qPCR of the
MTND1 and 18S rDNA genes and were normalized to untreated cells.vier Inc.
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dramatic effect on mt-mRNA stability, protein synthesis,
OXPHOS complex assembly, or function. If, however,
newly synthesized mitochondrial proteins are not being
perfectly assembled, the activity of some OXPHOS com-
plexes may be subtly compromised, resulting in electron
escape during the natural electron transfer and generating
increased reactive oxygen species. Superoxide and
peroxide production in the mitochondria were therefore
measured with mitoSOX and dihydrorhodamine 123
(DHR), respectively, at day 3 of siRNA-mediated mtRF1a
depletion. Figure 5B shows a significant increase of these
levels over control, which was maintained through to day 6
(data not shown).
Increased ROS has recently been implicated as a mes-
senger for increased mitochondrial biogenesis (Moreno-
Loshuertos et al., 2006). Levels of mitochondrial cardio-
lipin (quantified using NAO) and mtDNA copy number
were assessed as a measure of increased mitochondrial
bulk/mass. As shown in Figure 5B, a significant increase
was also noted using both methods, consistent with
mtRF1a depletion causing an increase in mitochondrial
ROS production and mitochondrial mass. To use mtDNA
copy number per cell as an indicator of mitochondrial
mass, DNA was isolated from HeLa cells following expo-
sure to the nontargeting and mtRF1a-directed siRNAs
and real-time PCR employed to quantify mtDNA (ND1) rel-
ative to nuclear DNA (18S rDNA) (see the Experimental
Procedures). After depletion of mtRF1a by siRNA, there
was a relative 2.2-fold increase in the mtDNA levels com-
pared to untreated controls (Figure 5B, mt/nuc), consis-
tent with the 1.6-fold increase identified with NAO
(Figure 5B, NAO).
DISCUSSION
We report the characterization of a human mitochondrial
translation release factor, mtRF1a, based on the following
criteria: (1) sequence similarity to known release factors;
(2) mitochondrial localization, import, and cleavage of
the preprotein; (3) presence in mitochondria of all cell
types and tissues tested; (4) demonstration of release fac-
tor activity in vitro with E. coli ribosomes; (5) rescue of the
Dmrf1 respiratory deficiency in fission and budding yeast
in vivo; and (6) demonstration of a growth phenotype in
mtRF1a-depleted human cells. Scrutiny of the primary
structure of mtRF1a reveals similarities to the many other
release factor sequences retaining the classic GGQ tri-
peptide of the peptidyl-tRNA interaction site in the M do-
main (Frolova et al., 1999; Song et al., 2000; Figure S2).
There is greater similarity to the eubacterial RF1-type fac-
tors than to the omnipotent eRF1, consistent with this
protein recognizing only UAA and UAG codons. Human
mtRF1a showed no activity with UGA as codon. There
are two class I release factors in most prokaryotes. Both
are able to decode UAA, while UAG and UGA are recog-
nized by only RF1 or RF2, respectively. It has previouslyMolecularbeen shown that the basis of this sequence discrimination
is due to a tripeptide sequence in a structurally similar
region, PXT in RF1 types or SPF for RF2 (Ito et al.,
2000). MtRF1a carries PKT at position 206–208, rather
than the hexapeptide found in mtRF1, consistent with
this being an RF1-type release factor, terminating protein
synthesis at UAA and UAG codons.
Is mtRF1 a mitochondrial release factor? The identifica-
tion of mtRF1 was skillfully made through bioinformatic
mining of an EST database but without any data to support
either localization or function (Zhang and Spremulli, 1998).
We have now shown that both mtRF1 and mtRF1a are lo-
calized to mitochondria, but only mtRF1a was capable of
decoding UAA/UAG codons in our assays. Furthermore,
addition of mtRF1 to release assays programmed either
with mtRF1a or E. coli RF1 failed to compete for the ribo-
somal A site when UAG/UAA were present, suggesting
that mtRF1 was unable to recognize these codons (Fig-
ure S5). Although for mtRF1 neither detectable in vitro re-
lease activity nor suppression of a respiratory deficiency
of the yeast Dmrf1 was observed, we hypothesize that it
is indeed a mitochondrial release factor and is responsible
for decoding the noncognate stop codons AGG and AGA.
The absence of release activity with the E. coli ribosomes
may be due to the imposed use of a heterologous assay
system, as the E. coli system does not naturally terminate
with either codon. Sequence comparisons provide a com-
pelling case for this hypothesis, since it contains the GGQ
domain, has strong sequence similarity to other RF1-type
proteins, and has a three residue extension immediately
C-terminal to the PXT domain that is absent in all com-
parators (Table 1) that may underlie AGA/AGG decoding.
Further, since yeast exclusively use UAA/UAG as stop co-
dons, this could explain the lack of observed complemen-
tation in vivo.
In vivo and in vitro studies showed that mtRF1a does
possess release factor activity. Expression in yeast strains
devoid of their endogenous release factor restored mito-
chondrial translation, indicating ability to decode UAA/
UAG, while depletion in human cells led to a growth phe-
notype and elevated ROS production. How might the loss
of mtRF1a lead to increased ROS? The major source of
cellular ROS is the mitochondrial electron transfer chain,
in particular at the sites of electron transfer to and from re-
spiratory complexes I and III. All 13 polypeptides encoded
by the human mtDNA are members of four of the five
complexes that couple oxidative phosphorylation. These
complexes contain many polypeptides imported from
the cytosol and integrated together with the mitochondri-
ally encoded proteins in a complicated and incompletely
understood process of assembly. The 13 mitochondrial
polypeptides are highly hydrophobic, being putatively
translated at the membrane surface and nursed by the
membrane protein Oxa1 that aids in the assembly process
(Liu and Spremulli, 2000). In the absence of translation ter-
mination, nascent proteins will be inserted into the mem-
brane but will also still be attached to the ribosome via
the P site bound peptidyl-tRNA. It is understood that thisCell 27, 745–757, September 7, 2007 ª2007 Elsevier Inc. 753
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but release factor activity at the ribosome dramatically ac-
celerates this natural process (Schmeing et al., 2005).
However, it is possible that subtle temporal effects on
the assembly process following siRNA-mediated knock-
down may lead to assembled complexes with minor de-
fects in electron transfer, leading to increased loss of elec-
trons in the form of ROS. A similar situation has recently
been reported for trans-mitochondrial murine cybrids, in
which the same mtDNA polymorphism in different nuclear
backgrounds led to modulations in ROS production and
mitochondrial cell mass without any dramatic effect on
OXPHOS complex activities (Moreno-Loshuertos et al.,
2006). A second possibility, that we have discounted, is
that the ribosome might stall at the termination site and
in the absence of a release factor shift-reading frame,
leading to C-terminal extensions mainly of polylysine
due to the proximity of the poly(A) tail. First, in the only
characterization of a human mt-mRNA lacking a termina-
tion codon, the mt-mRNA was rapidly degraded following
translation, probably due to the translating ribosome
pushing away the natural poly(A)-associated protein(s)
leaving naked RNA prone to RNase digestion (Temperley
et al., 2003). In the study presented here, there is no evi-
dence of decreased mt-mRNA stability. Second, although
only short polylysine extensions would be predicted to be
added to most mitochondrial polypeptides, ATPase 8, in
contrast, would increase substantially in size, as it is trans-
lated from the 50 part of the bicistronic RNA14. Following
depletion of mtRF1a, there is no evidence of increased
size in this or any newly synthesized mitochondrial pro-
teins. Third, when we have used an antibody specific to
polylysine, we do not see any new mitochondrial products
(data not shown).
In summary, we report the identification and biochemi-
cal characterization of a human mitochondrial translation
release factor, mtRF1a, that decodes the major stop co-
dons UAA and UAG. This should now be included in the
growing list of mitochondrial translation factors, mutations
of which could underlie the mitochondrial dysfunction in
an increasing number of patients for whom nuclear-
encoded mutations have yet to be determined.
EXPERIMENTAL PROCEDURES
Production of GFP and GST Fusion Constructs and Cloning
into Yeast Expression Vectors
Exact details of primers and construct design are given in the Supple-
mental Experimental Procedures.
Yeast Growth Conditions, Plasmid and General Strain
Constructions, and Complementation Assays
All yeast strains used in this study are detailed in Table S1.
Yeast media, general genetic techniques, and transformation proto-
cols were as described in Chiron et al. (2005). Briefly, whereas media
containing 2% glucose was fermentable for both yeasts, nonferment-
able conditions were achieved in media containing as sole carbon
source 2% glycerol (S. cerevisiae), or for S. pombe 3% glycerol/etha-
nol or 2% galactose and 0.1% glucose.754 Molecular Cell 27, 745–757, September 7, 2007 ª2007 ElsProduction of an S. pombe Dmrf1 Strain
A single S. pombe protein, encoded by gene Spac2f7.17, was found to
have a high level of identity (65%) with both E. coli RF1 and S. cerevi-
siae Mrf1. The ORF was PCR amplified using a cDNA library as tem-
plate and cloned into the BamHI site of the pTG1754 expression plas-
mid. An S. pombe Dmrf1::KanR strain (NB329) was constructed in the
wild-type recipient strain NB205-6A (Chiron et al., 2005) by using
a PCR disruption strategy with hybrid mrf1-KanR oligonucleotides as
described in (Chiron et al., 2005). Clones showing delayed growth on
galactose medium were proved by PCR to contain the correct inser-
tion. Crossing to a wild-type followed by sporulation and tetrad analy-
sis showed a 2:2 cosegregation of the geneticin resistance and slow
galactose growth. Transformation with the mrf1Sp plasmid restored
growth on galactose, showing that the mitochondrial DNA was intact
in this strain.
Spectroscopic Analyses
Cytochrome spectra were recorded from transformants of both yeasts
grown on solid medium. Cells were harvested, dried, and mixed with
sodium dithionite to fully reduce the cytochromes and were frozen in
liquid nitrogen before recording the absorbance of the samples at
wavelengths from 630 to 490 nm (spectrophotometer Cary 400). Peaks
were the following, for S. cerevisiae or S. pombe, respectively: cyto-
chrome c (546 or 548 nm), cytochrome c1 (552 or 554 nm), cytochrome
b (558 or 560 nm), and cytochrome aa3 (602 or 603 nm).
Overexpression and Purification of Human Mitochondrial
and Bacterial Proteins
E. coli strain Rosetta(DE3)pLysS (Novagen) was transformed with con-
structs for the overexpression of the human mitochondrial RFs that
were purified as detailed in the Supplemental Experimental Proce-
dures. E. coli RF1 was overexpressed and purified from strain BL21
pLysS following the protocol described in Tate and Caskey (1990).
Mitochondrial Import Assays
Reactions (20 ml) containing 10 ml rabbit reticulocyte lysate (Promega),
35 mCi EasyTag express protein labeling mix (NEG-772, PerkinElmer),
and 17.5 mM amino acids mix lacking methionine (Promega) were pro-
grammed with 5 mg of in vitro-transcribed RNA (synthesized using Am-
pliScribe, Epicenter) for 1 hr at 30C, after which 5 mM cold methionine
and 250 mM sucrose were added followed by a further 15 min incuba-
tion before ultracentrifugation at 125 kg for 30 min at 4C.
Rat liver mitochondria were isolated as previously described
(McGregor et al., 2001). Each 100 ml import reaction contained 200
mg of isolated mitochondria and 5 ml of the in vitro-translated protein
in isolation buffer (220 mM Mannitol, 70 mM sucrose, 10 mM HEPES
[pH 7.4], 1 mM MgCl2, 1 mM EGTA) supplemented with 1 mM ATP,
1 mM NADH, 20 mM succinate, and 50 mM CCCP as indicated. Reac-
tions were incubated for 1 hr at 30C, after which 5 mg Proteinase K
was added to a subset of reactions followed by a further 30 min incu-
bation on ice. PMSF (1 mM) was added to each reaction prior to cen-
trifugation at 13 kg for 1 min at 4C. Pellets were washed in isolation
buffer, repelleted, and resuspended in dissociation buffer prior to sep-
aration by SDS PAGE. Visualization was effected by PhosphorImage
analysis with ImageQuant software (Molecular Dynamics, GE Health-
care).
Cell Preparations and Western Analysis
Details of all yeast and human cell preparations and protein analysis
techniques are given in the Supplemental Experimental Procedures.
In Vitro Translation Termination Assay
This was performed essentially as described (Caskey et al., 1971; Tate
and Caskey, 1990) with modifications detailed in the Supplemental
Experimental Procedures. To generate the f[3H]met-tRNAmet, the fol-
lowing were combined to give the final concentrations indicated: caco-
dylate buffer (100 mM [pH 6.8]), 3.5 mM leucovorin (Sigma) as theevier Inc.
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specific tRNA (Sigma), 1.2 mM ATP, 1 mM DTT, 10 mM MgCl2, 3.8 nmol
L-[methyl-3H] methionine (GE Healthcare), and cold methionine up to
21.8 nmol, with the aminoacyl tRNA synthetase. This was incubated
for 30 min at 37C. Ribosomal substrate (amounts given are per
50 ml assay) was prepared by incubation of 70S ribosomes (5 pmol)
with AUG (250 pmol) and f[3H]met-tRNAmet (2.5 pmol) in 20 mM Tris-
HCl (pH 7.4), 10 mM Mg(OAc)2,150 mM NH4Cl at 30
C for 20 min.
This ‘‘activated’’ ribosomal substrate was stored on ice prior to inter-
rogation with release factors for activities with selected codons. Stan-
dard release reactions were as described in the Supplemental Exper-
imental Procedures, with f[3H]met in the supernatant quantified as an
indicator of release activity.
siRNA Transfection
siRNA transfection was performed using standard methods as de-
tailed in the Supplemental Experimental Procedures.
Free Radical and Mitochondrial Mass Measurements
MitoSOX (Molecular Probes) was prepared in DMSO and diluted to
5 mM in DMEM medium lacking serum. Cells were then incubated for
10 min at 37C, washed before resuspension in 2 ml DMEM-lacking
serum, and passed through a Partec PAS flow cytometer (Mu¨nster,
Germany). Forward and side scatter data were collected, as was auto-
fluorescence of unstained cells. Gating then allowed elimination of de-
bris and apoptotic cells from the analyses. Red fluorescence emission
resulting from MitoSOX staining was detected and median fluores-
cence intensity analyzed using FloMax software. The flow cytometer
was calibrated using fluorescent microspheres. Each measurement
was performed in triplicate based on 10,000 events and the experi-
ment repeated on four independent occasions.
Dihydrorhodamine 123 (DHR, Molecular Probes) or nonyl acridine
orange (NAO, Molecular Probes) was resuspended in DMSO, diluted
to 30 mM (DHR) or 10 mM (NAO) in DMEM-lacking serum, added to
cells, and incubated at 37C for 30 (DHR) or 10 (NAO) min. Cells
were then washed before resuspension in 2 ml DMEM-lacking serum
and the green fluorescence emission analyzed as above.
Relative Quantification of mtDNA Copy Number
Real-time PCR was performed on DNA isolated from cells digested
with Proteinase K (2 mg/ml final) in TE buffer (pH 7.4), 1% SDS that
was extracted with phenol and ethanol precipitated.
PCR primer and fluorogenic FAM probes for regions of mitochondrial
ND1 (forward primer, L3485–3504; reverse primer, H3532–3553;
probe, L3506–3529; Anderson et al. [1981]) and nuclear 18S (forward
primer, 1050–1071; reverse primer, 1095–1115; probe, 1074–1093, ac-
cession number M10098) genes were designed using Primer Express
software (Applied Biosystems). Each 25 ml reaction was performed in
duplicate on three independent samples. To each DNA sample
(10 ng) was added 12.5 ml TaqMan Universal PCR MasterMix (Applied
Biosystems), primers (300 nM final each), fluorogenic probes (100 nM
final), and H2O. PCR and fluorescence analysis was performed using
the Perkin Elmer GeneAmp 5700 sequence detection system. The am-
plification profile was 50C, 2 min; 95C, 10 min; 40 cycles of 95C, 15 s,
and 60C, 1 min. Threshold cycle number (Ct) was calculated with
GeneAmp 5700 SDS software v1.7 (Applied Biosystems).
S. pombe mitochondrial DNA was extracted from transformed cells
grown in minimal medium lacking uracil at 28C or 36C and analyzed
by Southern blotting with either the 1.3 kb arg1Sp nuclear gene ORF
(accession SPCC777.09c) or the pDG3 plasmid containing the full
S. pombe mitochondrial DNA cloned on pBR322 as described in
Chiron et al. (2005).
De Novo Mitochondrial Protein Synthesis
Protein translation in human cells was performed essentially as de-
scribed (Chomyn, 1996) and detailed in the Supplemental Experimen-
tal Procedures.MolecularDetermination of mRNA Poly(A) Tail Length
This method was described in detail in Temperley et al. (2003). All rel-
evant primers used in this study are given in the Supplemental Exper-
imental Procedures.
Respirometry
High-resolution respirometry was performed at 37C using an Oro-
boros Oxygraph-2K (Oroboros Instruments, Innsbruck, Austria) essen-
tially as detailed in Hutter et al. (2004). Approximately 0.5–13 106 cells
were added to the chamber in 2 ml of respiration buffer (glucose free
DMEM, 10% [v:v] FCS, 0.11 mg/ml-1 Na pyruvate, 0.9 mg/ml galac-
tose), and routine respiratory oxygen flux (R) was established over
15 min with automatic deduction of background flux using the online
DatLab software (Oroboros Instruments, Innsbruck, Austria). ATP syn-
thase was then inhibited (oligomycin, 1 mg/ml) and the rate measured
(Ro). Fully uncoupled flux (Ru) was then determined by sequential titra-
tion with 0.5 mM boluses of FCCP until maximal rates were observed.
Respiration was fully inhibited by the addition of rotenone (complex I
inhibitor, 0.5 mM final) and antimycin A (complex III inhibitor, 2.5 mM).
Where necessary, sporadic reaerations were performed to avoid oxy-
gen limitation during these measurements, cell counts were made us-
ing a small aliquot of cells at the end of the experiment, and rates were
then normalized to pmol oxygen consumed per 106 cells per unit time.
To assess the relative coupling, three ratios were calculated: the respi-
ratory control ratio (RCR, o˜Ru/o˜Ro), the uncoupling control ratio (UCR,
o˜Ru/o˜R) as a measure of respiratory reserve capacity, and a combina-
tion of these two ratios (RCRp, o˜R o˜Ro/o˜Ru) to determine the propor-
tion of phosphorylation-related respiratory capacity.
Statistical Analysis
Where required, Student’s unpaired t tests were used to determine the
significance of values as indicated in figure legends. Values of p < 0.05
were recorded as statistically significant.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, one table, and five figures and can be found
with this article online at http://www.molecule.org/cgi/content/full/27/
5/745/DC1/.
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